Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on ...

New Commercial Supply Contracts for Vafseo® (vadadustat) secured, bringing availability and dialysis organization coverage to nearly 100% of patients on dialysis in U.S. Akebia Therapeutics ...

On Wednesday, H.C. Wainwright analysts maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA). The firm's endorsement follows Akebia's announcement on January 13 that the U.S. commercial ...